Back to top
more

OncoSec Medical Incorporated (ONCS)

(Delayed Data from NSDQ)

$0.57 USD

0.57
329,997

+0.01 (1.77%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.57 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

OncoSec Medical Incorporated [ONCS]

Reports for Purchase

Showing records 1 - 20 ( 113 total )

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 1

08/16/2022

Daily Note

Pages: 4

Termination of Coverage

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 2

06/23/2022

Company Report

Pages: 6

BUY: Transmitting from the Blind II - Reports on the 10q

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 3

03/17/2022

Company Report

Pages: 6

BUY: Transmitting from the Blind Reports on the 10k

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 4

12/21/2021

Company Report

Pages: 6

BUY: What?s Next?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 5

12/21/2021

Company Report

Pages: 6

BUY: What?s Next?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 6

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ONCS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 7

07/07/2021

Company Report

Pages: 6

BUY: Merck Comes Onboard: Keytruda + TAVO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 8

07/07/2021

Company Report

Pages: 6

BUY: Merck Comes Onboard: Keytruda + TAVO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 9

06/14/2021

Company Report

Pages: 6

BUY: Reports the Third Quarter with $54M in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 10

04/19/2021

Company Report

Pages: 7

BUY: Picks up a CE Mark for GenPulse

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 11

03/15/2021

Company Report

Pages: 7

BUY: KOL Webinar on Anti-PD-1 Checkpoint Refractory Metastatic Melanoma Landscape

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 12

02/12/2021

Company Report

Pages: 7

BUY: Cash on the Balance Sheet - Melanoma Focus + COVID

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 13

11/25/2020

Company Report

Pages: 7

BUY: Cliniporator A Faster Pathway for Internal Cancers and an Enhanced COVID Response in Grandma and Grandpa

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 14

11/09/2020

Company Report

Pages: 7

BUY: TheKeyNote Trial Hits a High Note

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 15

08/27/2020

Company Report

Pages: 7

BUY: Raises $15M and Starts Phase 2 NeoAdjuvant at Moffit

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 16

12/14/2018

Company Report

Pages: 6

Dropping coverage following disappointing melanoma data.

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 17

11/07/2018

Company Report

Pages: 7

Preliminary Phase 2b Data Disappoint; Downgrade to Neutral and Reduce Price Target to $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 18

11/07/2018

Company Report

Pages: 6

Down note on KEYNOTE - Neutral

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 19

10/29/2018

Daily Note

Pages: 9

Immuno-Oncology Key Opinion Leader Conference Call Recap

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: OncoSec Medical Incorporated

Industry: Medical - Biomedical and Genetics

Record: 20

10/25/2018

Company Report

Pages: 5

TAVO?s Abscopal Effects in Preclinical Models Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party
// eof